Secant Group, a global biomaterials leader, offers an innovative controlled active release technology platform Hydralese™, a bioresorbable polymer that enables sustained drug delivery via surface erosion. Specializing in formulation and development services for a variety of API’s and finished dosage forms including implantable rods and microspheres, the company has the expertise to support pharmaceutical customers seeking to improve patient compliance and healthcare globally.